Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESD | P10768 | 1/20 | 0.49 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.49 |
| ▸ | MMP2 | P08253 | 8/20 | 0.47 |
| ▸ | MMP8 | P22894 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7131258 | 0.87 | MAOA (0.48) | ESDPRKCZMMP2MMP8MEN1 | |
| SCHEMBL6298325 | 0.82 | ESD (0.60) | ESDPRKCZMMP2MMP8MEN1 | |
| SCHEMBL27997398 | 0.73 | ESD (0.61) | ESDPRKCZMEN1HSP90AA1KMT2A | |
| SCHEMBL6298090 | 0.73 | ESD (0.61) | ESDPRKCZMEN1HSP90AA1KMT2A | |
| SCHEMBL6294124 | 0.72 | ESD (0.52) | ESDMEN1HSP90AA1KMT2A | |
| SCHEMBL6294160 | 0.71 | ESD (0.58) | ESDPRKCZMEN1HSP90AA1KMT2A | |
| SCHEMBL6292699 | 0.71 | ESD (0.75) | ESDPRKCZMEN1HSP90AA1KMT2A | |
| SCHEMBL27997620 | 0.69 | ESD (0.65) | ESDPRKCZMEN1HSP90AA1KMT2A | |
| SCHEMBL7129326 | 0.69 | PRKCZ (0.46) | PRKCZKIF11 | |
| SCHEMBL7039863 | 0.68 | MEN1 (0.61) | MMP2MMP8MEN1HSP90AA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | EPOR, VEGFA, TEK | ESD 2918/4885PRKCZ 1874/4885MMP2 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.